Rakovina Therapeutics Inc RKV

Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR inhibitor programVANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced a research collaboration with Boston-based Celvion Therapeutics (“Celvion”) to leverage Celvion’s proprietary EM

Yale physician-scientist and biotech entrepreneur Dr. Ranjit Bindra brings deep expertise in DNA repair, synthetic lethality and brain tumor therapeuticsVANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Dr. Ranjit Bindra, MD, PhD, to its Scientific Advisory Board (“SAB”). Dr. Bindra is the Scienti

Chair of Translational Neuro-Oncology at the University of Manchester, previously a member of the Company's Scientific Advisory Board, elected at the 2026 Annual General MeetingVANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Prof. Petra Hamerlik to its board of directors at the Company’s annual

All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced its financial results for the three and six months ended June 30, 2026 (“Q2 2026” and “YTD 2026”, respectively), and provided an update on recent corporate developments. Q2 2026 Financial Highl

Financing completed at the full upsized amount following strong investor demandVANCOUVER, British Columbia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the second and final tranche (the “Second Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2

VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce the results of voting at its 2026 annual general meeting of shareholders held on August 18, 2026, in Toronto, Ontario (the “Meeting”). All five members of the Company’s board of directors named as nominees in its management information circular dated July 14,

Expanded financing broadens Rakovina’s strategic investor base and reinforces confidence in its AI-powered oncology platformVANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”),

VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)( FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announces a non-brokered private placement offering (the “Offering”) of up to $1.5 million. Pursuant to the Offering, Rakovina will issue up to 15 million equity units (“Units”) at an offering price of $0.10 per Unit, with each Unit consisting of one

Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies through the service of CDS Clearing and Depository Services Inc.Company NameRecord DateMeeting DateType Apex Critical Metals Corp. June 8, 2026July 10, 2026AG Ashley Gold Corp. June 9, 2026July 14, 2026AS Athena Gold Corporation June 9, 2026July 24, 2026AS CORE SILVER CORP. *May 12, 2026June 16,...

VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7J0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a corporate update. As Rakovina enters 2026, the Company is advancing its three primary drug discovery prog

AI-Designed Dual ATR-mTOR Inhibitor Demonstrates In Vivo Efficacy; Novel LNP Formulation of Bifunctional PARP/HDAC Inhibitor kt-3283 Successfully CharacterizedVANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced the presentation of new preclinical data from two of its lead programs at the 2026